Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email



Pemafibrate (K-877) attenuates postprandial hypertriglyceridemia in mice

Pemafibrate is a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM?) with higher activity and selectivity for the PPAR? receptor than the fibrate drugs. Pemafibrate has been shown to significantly reduce triglycerides in individuals with hypertriglyceridaemia or atherogenic dyslipidaemia, and has recently received regulatory approval for the management of dyslipidaemia in Japan.
The current study compared the effect of pemafibrate (0.0005%) or fenofibrate (0.05%), in a mouse model of diet-induced hypertriglyceridaemia. Treatment with pemafibrate was shown to decrease postprandial levels of triglycerides and apolipoprotein B-48, as well as reduce the postprandial accumulation of triglyceride-rich lipoproteins and chylomicron remnants. These findings suggest that pemafibrate may have potential benefit in attenuation of postprandial hypertriglyceridaemia, a risk factor for cardiovascular disease.
A novel Selective PPAR? Modulator (SPPARM?), K-877 (Pemafibrate), attenuates postprandial hypertriglyceridemia in mice.

Sairyo M, Kobayashi T, Masuda D, Kanno K, Zhu Y, Okada T, Koseki M, Ohama T, Nishida M, Sakata Y, Yamashita S.